Dr. Chen Huang , Shenzhen Institute of Advanced Technology (SIAT) Chinese Academy of Sciences (CAS) , China

Dr. Chen Huang is an Associate Researcher at the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences. She earned her Ph.D. in 2018 from the University of the Chinese Academy of Sciences. Her primary research lies at the intersection of female reproductive endocrinology and metabolic diseases, focusing on how adverse intrauterine environments impact long-term offspring health. Dr. Huang has authored over 20 SCI-indexed papers and holds 18 published patents with one under review. She has played significant roles in national and regional projects funded by the NSFC and Shenzhen Innovation Commission. Her notable contributions include identifying novel peptides with therapeutic potential in NAFLD and TNBC, and exploring molecular mechanisms behind pregnancy complications. Her impactful work, especially on metabolitin (MTL) and chemerin/GPR1 signaling pathways, has earned recognition in high-impact journals like Journal of Hepatology. Dr. Huang’s commitment to translational research places her at the forefront of biomedical innovation in women’s health.

Publication Profile:

Scopus

Strengths for the Award:

Dr. Chen Huang exemplifies academic and scientific excellence through her impactful research in the fields of female reproductive endocrinology and metabolic diseases. Her contributions have led to meaningful advancements in understanding the molecular mechanisms that govern maternal-fetal health and associated disorders such as NAFLD, pregnancy complications, and cancer.

Key strengths include:

Scientific Innovation: She has identified and characterized novel peptide hormones such as metabolitin (MTL) and explored their therapeutic roles, a groundbreaking approach in targeting metabolic and oncological diseases.
High-Quality Publications: With around 20 SCI-indexed journal articles, including those in high-impact journals like Journal of Hepatology and Molecular Therapy – Oncolytics, her work is widely recognized in the scientific community.
Patent Portfolio: Dr. Huang has published 18 patents, with another under review, demonstrating her strong translational focus and commitment to real-world biomedical applications.
Research Leadership: She has successfully led multiple competitive national and regional research projects funded by the NSFC and Shenzhen Innovation Commission.

Areas for Improvement:

While Dr. Huang’s research output and contributions are impressive, certain enhancements could further elevate her global profile:

International Exposure: Engaging in more international collaborative projects or joint publications with global institutes could broaden the impact of her research.
Editorial and Professional Roles: Participation in editorial boards, peer review panels, or scientific committees would enhance her leadership presence in the scientific ecosystem.
Industry Engagement: Establishing collaborations with biotech or pharmaceutical industries could increase the translational value of her work and open pathways for clinical applications.

🎓 Education:

Dr. Chen Huang received her Ph.D. in 2018 from the University of the Chinese Academy of Sciences. Her doctoral research laid the foundation for her interest in female reproductive endocrinology and metabolic disorders, combining clinical insight with molecular research. Throughout her academic training, she focused on identifying the mechanistic links between endocrine disruptions during pregnancy and their long-term effects on offspring health. She has continually built upon this expertise through advanced training and interdisciplinary collaborations. Her educational background provided her with a robust understanding of molecular biology, endocrine physiology, and metabolic pathways, which she has applied in various research contexts—from liver disease to cancer biology. Her academic excellence was further highlighted by her early co-first authorship in high-impact journals during her Ph.D., demonstrating her ability to lead and innovate in collaborative research projects even in early stages of her career.

🧪 Experience:

Dr. Chen Huang is currently serving as an Associate Researcher at the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences. Since completing her Ph.D. in 2018, she has led and contributed to several key research projects, including those funded by the National Natural Science Foundation of China and the Shenzhen Science and Technology Innovation Commission. Her experience spans both basic and translational science, with an emphasis on hormonal regulation and metabolic diseases during pregnancy. She has collaborated with renowned scientists like Dr. Teng and Dr. Enkui Duan, contributing to the discovery of new peptide hormones such as metabolitin (MTL). Her professional experience is enriched by her ability to translate complex molecular findings into therapeutic strategies, especially in contexts like NAFLD and triple-negative breast cancer. With over 20 peer-reviewed SCI publications, her work reflects a consistent commitment to advancing biomedical research with clinical relevance.

🔬 Research Focus:

Dr. Chen Huang’s research focuses on the molecular underpinnings of female reproductive endocrinology and metabolic diseases, particularly within the context of pregnancy. She investigates how adverse intrauterine environments affect fetal development and contribute to long-term health issues in offspring. Her work explores key hormone-receptor interactions, such as the role of novel peptides (e.g., metabolitin) in liver disease and cancer. A major thread of her research also addresses the function of adipokines and their signaling pathways in pregnancy complications such as miscarriage and preeclampsia. Using both in vivo and in vitro models, she studies the regulatory mechanisms of trophoblast invasion, spiral artery remodeling, and immune cell interactions in the placenta. Her work integrates endocrinology, immunology, and developmental biology to identify new therapeutic targets. With an h-index of 12, she is recognized for her impactful publications and innovation in peptide-based treatments.

📚 Publications Top Notes:

🧬 Metabolitin (MTL) as a GPRC6A ligand improves NAFLD – Journal of Hepatology, 2020 (Co-first author)
🧪 Peptide blocks chemerin/GPR1 signaling to inhibit TNBC growth – Molecular Therapy – Oncolytics, 2020 (First author)
🔍 Adipokine promotes placental trophoblast invasion and vascular remodeling – Am J Physiol-Endocrinol Metab, 2019 (Co-first author)
🔬 mTOR hypoactivity causes trophectoderm failure via lysosomal activation – Cell and Bioscience, 2023

Conclusion:

Dr. Chen Huang is a highly deserving candidate for the Best Researcher Award. Her research contributions stand out in both innovation and societal impact, especially in the crucial domains of reproductive health and metabolic diseases. With a consistent publication record, numerous patents, and demonstrated research leadership, she is poised to make even greater scientific contributions in the years ahead. Recognizing her with this a

Mingkun Yu | Cancer Cell Biology | Best Researcher Award

Posted on 23/04/202523/04/2025 by sciencefather

Dr. Mingkun Yu | Cancer Cell Biology | Best Researcher Award

Dr. Mingkun Yu , Binzhou Medical College Affiliated Traditional Chinese Medicine Hospital(Binzhou Traditional Chinese Medicine Hospital) , China

Dr. Mingkun Yu is an Associate Chief Physician at Binzhou Traditional Chinese Medicine Hospital, affiliated with Binzhou Medical College, China. He is an expert in integrating evidence-based medicine with traditional Chinese and Western medical practices, especially within oncology and ophthalmology. With over five years of clinical experience, Dr. Yu has made significant contributions to the field through impactful clinical research, trial designs, and methodological innovation. He is the recipient of a National Natural Science Foundation of China project and has led the development of national-level guidelines. Dr. Yu’s publications have gained high visibility, with citations and downloads from prestigious journals like BMJ. He collaborates with renowned experts worldwide and actively contributes as a peer reviewer for SCI journals. Known for his meticulous clinical approach and research rigor, Dr. Yu is a rising star in integrative medical science, particularly in addressing patient compliance and advancing myopia-related research strategies.

Publication Profile:

Orcid

✅ Strengths for the Award:

Academic Excellence
Dr. Yu has earned advanced degrees from top-tier traditional Chinese medicine institutions in China, culminating in a PhD focused on integrated clinical medicine—a rare and interdisciplinary specialty.
Proven Research Record
- Published 7 SCI-indexed papers (including in BMJ and Therapeutic Advances in Gastroenterology) and 5 Chinese core journal papers.
- First/corresponding author impact factor: 18.3; co-author cumulative impact factor: 112.
- One article with 9248 downloads, another cited 66 times—demonstrating strong academic reach and relevance.
Research Leadership
- Designed and led multiple RCTs, cohort studies, and cluster RCTs.
- Principal investigator of a National Natural Science Foundation of China project.
- Spearheaded the national-level guideline on myopia—a major public health concern in Asia.
Innovative Contributions
- Introduced target value analysis and conducted extensive patient compliance research in clinical trials.
- Integrated evidence-based methods with traditional Chinese medicine, a cutting-edge niche in global medical research.
Collaborations & Peer Review
- Collaborates with global leaders such as Paul Little, Gordon Guyatt, and Lehana Thabane.
- Reviewer for top SCI journals including European Journal of Integrative Medicine and BMC Geriatrics.

⚙️ Areas for Improvement:

Global Dissemination & Outreach
- Dr. Yu could further enhance his profile by increasing international speaking engagements, attending more global medical symposia, and joining international research societies.
Books or Monographs
- No books published yet. Authoring clinical reference books or practitioner guides would boost both practical impact and professional visibility.
Translational Research and Patents
- With only one published patent, there is scope to convert more research findings into innovative tools, treatments, or technologies for broader clinical application.
Professional Memberships
- Active memberships in professional research or clinical bodies could enhance his professional network and visibility in award circuits.

📚 Education:

Dr. Yu earned his Master’s degree in Evidence-Based Medicine (Oncology) from Beijing University of Traditional Chinese Medicine in 2021. His academic journey culminated in a PhD in Clinical Medicine (Integrated Traditional Chinese and Western Medicine) from Shandong University of Traditional Chinese Medicine in 2024. Throughout his education, Dr. Yu focused on bridging the gap between traditional Chinese therapeutic principles and contemporary Western medical methodologies. His doctoral research emphasized designing clinical trials, evaluating treatment efficacy using systematic review and meta-analysis, and developing methodologies for improving patient outcomes. His educational background also provided him with comprehensive knowledge in oncology, ophthalmology, acupuncture, and behavioral health, preparing him to implement innovative, integrative solutions in clinical practice. He was mentored by leading figures in evidence-based medicine and engaged in collaborative studies with international researchers, further enriching his global research perspective.

🩺 Experience:

With more than 5 years of experience in clinical medicine, Dr. Mingkun Yu has become a prominent practitioner and researcher in integrated traditional Chinese and Western medical care. As an Associate Chief Physician at Binzhou Traditional Chinese Medicine Hospital, he leads and participates in high-level clinical research projects, including randomized controlled trials and cohort studies. He has contributed to over 7 national-level research projects and served as principal investigator in hospital-based clinical studies. Dr. Yu’s areas of expertise include patient compliance strategies in oncology, evidence synthesis in myopia prevention, and methodological development for clinical trials. He is a frequent presenter at national and international conferences and has served as a reviewer for SCI-indexed journals. Dr. Yu is also involved in writing clinical practice guidelines and has been recognized for his scientific contributions through research awards and publications in high-impact journals.

🔬 Research Focus:

Dr. Mingkun Yu’s research lies at the intersection of evidence-based medicine and integrated Chinese and Western clinical practices. His key focus areas include patient compliance in oncology, risk factor identification and prevention strategies for myopia, and designing robust clinical trials like RCTs, cohort, and cluster studies. He actively develops and applies systematic review methodologies, meta-analyses, and guideline development processes to ensure high-impact clinical outcomes. Dr. Yu has innovated in the area of patient compliance by applying qualitative synthesis and target value analysis, improving retention and adherence in clinical trials. He is particularly invested in the development of guidelines for myopia in children and adolescents and has published widely in SCI journals. His collaboration with global experts such as Paul Little, Gordon Guyatt, and Lehana Thabane strengthens the international relevance of his work. Through this multifaceted research approach, Dr. Yu aims to bridge traditional wisdom with modern scientific rigor.

📝 Publications Top Notes:

📄 Pseudomyopia as an independent risk factor for myopia onset: a prospective cohort study among school-aged children – British Journal of Ophthalmology, 2024
📘 The Process factors and improvement strategies of patient compliance and retention in clinical trials: a synthesis of qualitative research – Inplasy Report, 2021
📚 Berberine for diarrhea in children and adults: a systematic review and meta-analysis – Therapeutic Advances in Gastroenterology, 2020

🧾 Conclusion:

Dr. Mingkun Yu stands out as a highly deserving candidate for the Best Researcher Award due to his cross-disciplinary research integrating traditional Chinese and Western medicine, his leadership in national clinical trials, impactful publications, and commitment to clinical innovation. His scholarly output is not only substantial but also highly cited and widely read, reflecting real-world influence and academic excellence.

With a growing international research presence, a unique focus on culturally integrated methodologies, and an impressive trajectory of innovation and collaboration, Dr. Yu clearly embodies the ideals of a next-generation clinical research leader.

Dia Aldeen Alfaki | Immunology Cellular Interactions | Best Researcher Award

Posted on 14/03/202514/03/2025 by sciencefather

Mr. Dia Aldeen Alfaki | Immunology Cellular Interactions | Best Researcher Award

Mr. Dia Aldeen Alfaki , Alzaiem Alazhari University , Sudan

Dia Alfaki is a Sudanese biomedical scientist with a Master of Biomedical Sciences and extensive experience in haematology, molecular biology, and immunology. His research focuses on the complexities of disease mechanisms and therapeutic solutions, particularly within immunology. As a junior researcher and PG Member of the British Society of Immunology, Dia has contributed significantly to studies on malaria and immune responses. His academic background includes a Master’s degree from Alzaiem Alazhari University and a Bachelor’s degree from Omdurman Islamic University. Dia’s dedication to understanding disease complexities through research is reflected in his growing academic presence and expertise in clinical laboratory techniques. He is committed to advancing scientific knowledge and improving healthcare solutions through his research endeavors.

Publication Profile:

Orcid

Strengths for the Award:

Dia Alfaki has a remarkable blend of educational qualifications, practical experience, and academic research, making him highly suitable for the Research for Best Researcher Award. His work spans critical areas in biomedical sciences, with a special focus on immunology, haematology, and molecular biology, especially in relation to infectious diseases like malaria. His Master’s research on immune responses to Plasmodium falciparum infection stands out, demonstrating his ability to identify novel immunological markers. His published work in well-regarded journals like Microbiologia Medica and Immunology & Cell Biology further showcases his expertise. He has actively contributed to the scientific community through various international conferences, highlighting his commitment to advancing research. His work at G42 Healthcare underscores his technical skills in molecular diagnostics and cutting-edge biomedical research. His collaborative nature, critical thinking, and proven leadership in research make him a strong contender for this award.

Areas for Improvement:

While Dia Alfaki has a solid foundation in immunology and biomedical research, further expansion of his research portfolio into diverse therapeutic fields could enhance his profile. Gaining more experience in clinical settings beyond molecular labs could provide him with a broader perspective in healthcare applications. Additionally, his involvement in multi-disciplinary research collaborations across diverse disease areas such as oncology and genomics would elevate his impact on global biomedical challenges. Developing greater expertise in bioinformatics tools and integrating them into his molecular research would further refine his analytical skills and position him as an even more influential scientist in his field.

Education:

Dia Alfaki holds a Master’s degree in Biomedical Sciences from Alzaiem Alazhari University (2014-2016), where he specialized in Medical Laboratory Sciences with a focus on Haematology and Blood Transfusion, achieving a CGPA of 3.19/4.0. He completed his Bachelor’s degree in Medical Laboratory Sciences from Omdurman Islamic University (2007-2011), where he excelled in Hematology and Immunohematology. Additionally, Dia is pursuing certification as an International Medical Lab Technologist in Hematology (ASCPi) from the American Society for Clinical Pathology (2022-2025). His academic and professional development demonstrates a strong foundation in biomedical sciences, preparing him to make significant contributions to immunology research and clinical diagnostics.

Experience:

Dia Alfaki has worked as a Molecular Lab Technologist at G42 Healthcare (Biogenix Molecular Labs) from 2020-2023, contributing to advanced molecular research and diagnostics. His expertise spans a wide range of laboratory techniques, particularly in immunology, molecular biology, and hematology. Throughout his career, Dia has been involved in various research projects, including his Master’s thesis focused on the immune response to Plasmodium falciparum infection. He has also contributed to several high-impact publications, collaborating with experts in the field of malaria, immune phagocytosis, and cancer immunology. His role in molecular diagnostics has allowed him to apply his research findings to real-world clinical settings, furthering the understanding of disease pathology and therapeutic interventions.

Awards and Honors:

Dia Alfaki has been recognized for his significant contributions to biomedical science, particularly in immunology research. He participated in prominent international conferences, including the 6th European Congress of Immunology (2022) and the American Association for Cancer Research Annual Meeting (2021). His ongoing work in malaria immunology and cancer immunology is highly regarded in scientific communities. As a PG Member of the British Society of Immunology since 2021, Dia continues to gain recognition for his research on immune responses and inflammation. His work has also been highlighted in various prestigious journals, where his research on malaria and immune responses has earned accolades. These honors reflect his commitment to advancing scientific knowledge and improving healthcare through rigorous research.

Research Focus:

Dia Alfaki’s research is primarily focused on immunity, inflammation, cancer immunology, and molecular oncology. His work emphasizes understanding disease mechanisms, particularly the immune responses involved in infections like malaria and the pathogenesis of diseases such as cancer. Dia is particularly interested in the role of immune mediators, phagocytosis, and molecular interactions in disease progression and therapy. His research aims to explore therapeutic perspectives in immunology, using molecular and cellular approaches to better understand disease complexities and improve treatment options. His publications highlight these areas, especially in the context of malaria and inflammatory immune responses. Dia is also committed to utilizing molecular techniques and bioinformatics tools to contribute to new therapeutic strategies for immunological diseases.

Publications Top Notes:

Patterns of Mannose-Binding Lectin (MBL) responses to Plasmodium falciparum infections in hyperendemic settings 📚🔬
Inflammatory immune mediators and Plasmodium falciparum infection: a cross-sectional study among Sudanese patients with severe and uncomplicated malaria 🌍🦠
Monocytes to lymphocytes ratio in peripheral blood and immunoglobulin IgE levels as indicators to Plasmodium falciparum infection in Sudan 📖🔬
The colorectal cancer microenvironment: Preclinical progress in identifying targets for cancer therapy 🦠🔬
Plasmodium falciparum and immune phagocytosis: characterization of the process 🦠💉

Conclusion:

Dia Alfaki is an outstanding researcher with a well-rounded background in biomedical sciences, molecular biology, and immunology. His research accomplishments, publications, and contributions to international conferences highlight his drive for advancing scientific knowledge, particularly in the area of disease mechanisms and immune responses. His strong academic foundation, coupled with his practical lab experience and active engagement with the scientific community, positions him as an excellent candidate for the Research for Best Researcher Award. With a few areas of growth in clinical practice and cross-disciplinary collaborations, he has the potential to become a leader in global biomedical research.

Huiying Fan | Host-Pathogen Interactions | Best Researcher Award

Posted on 07/12/202407/12/2024 by sciencefather

Dr. Huiying Fan | Host-Pathogen Interactions | Best Researcher Award

Dr. Huiying Fan , College of Veterinary Medicine, South China Agricultural University , China

Dr. Huiying Fan is a distinguished professor and doctoral supervisor at the College of Veterinary Medicine, South China Agricultural University, specializing in veterinary virology and immunology. As a core member of the Key Laboratory for Veterinary Vaccine Development, his expertise includes creating genetically engineered vaccines for animal viruses. Dr. Fan has published over 40 research papers in leading journals, including Journal of Virology and Emerging Microbes & Infections, and holds 11 invention patents. His career has been marked by significant contributions to animal virus research and vaccine development, with extensive involvement in national research programs. He has been recognized with several provincial and ministerial-level awards and is actively involved in scientific development and industry collaboration in China.

Publication Profile:

Scopus

Strengths for the Award:

Dr. Huiying Fan has demonstrated exceptional contributions to the field of veterinary virology and immunology, particularly in the development of vaccines for animal viruses. He is a recognized leader in the creation of genetically engineered vaccines, with over 40 SCI papers published in high-impact journals such as Journal of Virology, Emerging Microbes & Infection, and Vaccines. His involvement in groundbreaking research on the pathogenic mechanisms of viruses like avian influenza, porcine epidemic diarrhea, and African swine fever underscores his expertise. Furthermore, Dr. Fan has been granted 11 invention patents and is an influential figure in national research programs, such as the National Key Research and Development Program. His leadership as a professor and mentor, coupled with his ongoing innovations in virus detection and vaccine development, showcases his remarkable impact in the field.

Areas for Improvement:

While Dr. Fan’s scientific research has been groundbreaking, expanding his focus on broader global collaborations could enhance the scope of his work. In particular, his work could benefit from incorporating more interdisciplinary approaches, combining cutting-edge technologies such as artificial intelligence or big data analytics, which are becoming increasingly crucial in disease surveillance and vaccine development. Moreover, his research could further address the application of his vaccine technologies in low-resource settings, to maximize global health impact. Engaging more actively in science communication could also help translate his findings into policies or programs that benefit larger populations, both within China and internationally.

Education:

Dr. Fan completed his Ph.D. in Preventive Veterinary Medicine at the College of Veterinary Medicine, Huazhong Agricultural University, in June 2007. During his doctoral research, he focused on the study of veterinary diseases and virus-host interactions, laying a strong foundation for his future work in vaccine development. His commitment to advancing veterinary science continued through postdoctoral training, followed by his establishment as a professor at South China Agricultural University. His education reflects his dedication to merging academic research with practical applications for the improvement of animal health and disease prevention.

Experience:

Dr. Fan’s career began in 2007 as a professor at South China Agricultural University, where he became a leading figure in veterinary medicine. He has also contributed significantly to international research, evidenced by his six-month research visit to City University of Hong Kong in 2016. As a core member of several high-impact research initiatives, including the National Key Research and Development Program, he has played a vital role in advancing veterinary virology and vaccine development. Dr. Fan’s extensive expertise has led to collaborations across national projects and scientific endeavors, particularly in the realm of infectious diseases and immune responses in animals.

Awards and Honors:

Dr. Fan has received multiple prestigious awards throughout his career, including 8 provincial and ministerial-level honors. Notably, he was named a “Pearl River Science and Technology Star” in Guangzhou and recognized as a “Science and Technology Commissioner” by the People’s Government of Guangdong Province. His contributions to veterinary science have garnered recognition both within China and internationally, highlighting his commitment to scientific excellence and industry collaboration. These accolades underscore his leadership in veterinary vaccine research and his influence on public health initiatives concerning animal diseases.

Research Focus:

Dr. Fan’s primary research interests lie in the molecular design of genetically engineered vaccines for animal viruses, including those affecting poultry and swine. His studies explore the immune mechanisms and pathogenesis of viruses such as avian influenza and porcine viral diarrhea. In addition to his work on vaccine development, he investigates the use of innovative techniques, including CRISPR/Cas12a and proteomics, to better understand virus-host interactions and to improve diagnostic and therapeutic strategies for animal diseases. His focus on veterinary virology aims to enhance both animal and public health outcomes.

Publication Top Notes:

“A single immunization with H5N1 virus-like particle vaccine protects chickens against divergent H5N1 influenza viruses” 🐔🦠
“Influenza H7N9 Virus Hemagglutinin with T169A Mutation Possesses Enhanced Thermostability” 🦠❄️
“Immune Escape Mechanism and Vaccine Research Progress of African Swine Fever Virus” 🐖🦠
“Supplementation of H7N9 Virus-Like Particle Vaccine With Recombinant Epitope Antigen Confers Full Protection” 🦠💉
“PEDV infection affects the expression of polyamine-related genes inhibiting viral proliferation” 🐖🧬
“Proteome Analysis in PAM Cells Reveals That African Swine Fever Virus Can Regulate Intracellular Polyamines” 🧬🔬
“CRISPR/Cas12a Technology Combined with Immunochromatographic Strips for Portable Detection of ASF Virus” 🧬🦠
“Quantitative Proteomics Reveals Changes in Vero Cells in Response to Porcine Epidemic Diarrhea Virus” 🐖🔬
“Coimmunization with recombinant epitope-expressing baculovirus enhances protective effects of H5N1 vaccine” 💉🦠
“Either fadD1 or fadD2, Which Encode acyl-CoA Synthetase, Is Essential for the Survival of Haemophilus parasuis SC096” 🦠🔬
“Two Glycosyltransferase Genes of Haemophilus parasuis SC096 Implicated in Lipooligosaccharide Biosynthesis” 🧬🦠
“Recombinant baculovirus vaccine containing multiple M2e and adjuvant LT induces T cell-dependent protection against H5N1” 💉🦠
“BacMam virus-based surface display of IBV S1 glycoprotein confers strong protection against virulent IBV challenge” 🐔🦠
“Quantitative Proteomics by Amino Acid Labeling in Foot-and-Mouth Disease Virus-Infected Cells” 🐄🧬
“Quantitative proteomics using SILAC reveals protein and pathway regulation in porcine circovirus type 2 infected PK-15 cells” 🐖🧬

Conclusion:

Dr. Huiying Fan is undoubtedly a strong contender for the Research for Best Researcher Award, given his outstanding contributions to animal virus research, innovative vaccine design, and leadership in national research initiatives. His extensive publication record, patent portfolio, and recognition through prestigious awards highlight his scientific excellence. Although expanding his collaborative network and exploring interdisciplinary methodologies could elevate his impact further, Dr. Fan’s work has already had a profound effect on veterinary medicine and public health, making him a well-deserved nominee for this award.